Browsing by Author DE BLOIS Erik

Showing results 1 to 5 of 5
Publication YearJRC N°TitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2014JRC90200Influence of tumour size on targeted alpha therapy with 213Bi-[DOTA,Tyr3]octreotate (DOTA-TATE) in a small cell lung carcinoma (SCLC) mouse model.CHAN Ho-Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2016JRC100045Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotateCHAN Ho Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; BAUM Richard; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2015JRC96963The next step in increasing the efficacy of PRRT: Preclinical studies in vicvo and in vitro with 213Bi-[DOTA0,Tyr3]-octreotateCHAN Ho Sze; KONIJNENBERG M.w.; DE BLOIS Erik; KOELEWIJN S.j.; ANDERSON Tamara; NYSUS Monique; BREEMAN W.a.p.; ATCHER Robert; MORGENSTERN Alfred; BRUCHERTSEIFER Frank, et alArticles in periodicals and books
2014JRC88669Optimizing labeling conditions of 213Bi somatostatin analogues for receptor mediated process in preclinical modelsCHAN Ho-Sze; DE BLOIS Erik; KONIJNENBERG M.w.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; BREEMAN Wouter; DE JONG MarionArticles in periodicals and books
2016JRC101798Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyCHAN Ho Sze; DE BLOIS Erik; KONIJNENBERG M.w.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; NORENBERG Jeffrey; VERZIJLBERGEN Fred J; DE JONG Marion; BREEMAN WouterArticles in periodicals and books